An interventional study of End-tidal oxygen monitor in Critical Illness, Hypoxia and Respiratory Failure, sponsored by Sydney Local Health District. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Sydney Local Health District · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hypoxia with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Hypoxia · Australia.
Among the 10 studies in Hypoxia with a site in Australia, this one has the largest planned enrollment, is the only one that started in 2024, is one of 7 with no phase, and was the 10th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →3 of the 10 studies in Hypoxia with a site in Australia are open now. Recruiting first, the newest first:
Royal North Shore Hospital · Sites in Australia
Ages 18+
Australian and New Zealand Intensive Care Research Centre · Sites in Australia, Germany
Ages 18–65
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,400 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 28 across the 10 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 8 most frequent:
Sydney Local Health District is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Sydney Local Health District has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hypoxia with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rapid Sequence Intubation (RSI) is a high-risk procedure in the emergency department (ED). Patients are routinely preoxygenated (given supplemental oxygen) prior to RSI to prevent hypoxia during intubation. For many years anaesthetists have used end-tidal oxygen (ETO2) levels to guide the effectiveness of preoxygenation prior to intubation. The ETO2 gives an objective measurement of preoxygenation efficacy. This is currently not available in most EDs.
This trial evaluates the use of ETO2 on the rate of hypoxia during intubation for patients in the ED.
BACKGROUND AND INTRODUCTION
Rapid Sequence Intubation (RSI) is a common procedure in Emergency Departments (ED). However, it is a high-risk procedure and is associated with significant complications including hypoxia, failed intubation, hypotension, trauma and aspiration. (1-3) Specifically, hypoxia during intubation can lead to poor outcomes such as dysrhythmias, haemodynamic compromise, hypoxic brain injury and death and therefore oxygen desaturation is of primary concern during any intubation procedure. (4, 5) In order to prevent desaturation events during intubation, a number of steps are taken by clinicians. These include optimal patient positioning, adequate preoxygenation, assessment of airway anatomy and development of a detailed airway plan as well as the use of apnoeic oxygenation.(6)
Effective preoxygenation is vital to ensure that the patient does not develop hypoxia during the period between induction (administration of sedative and paralytic agents) and restoration of ventilation by successful endotracheal intubation or rescue breathing. Various methods of preoxygenation have been developed to wash the nitrogen out of the lungs (denitrogenation) which allows the functional residual capacity (FRC) to act as an oxygen reservoir during intubation, which prolongs safe apnoea time, therefore, preventing desaturation whilst an endotracheal tube (ETT) is placed.
Adequate preoxygenation is especially important for those patients at highest risk of hypoxia during the RSI. This patient group includes those with underlying lung pathology e.g. pneumonia, patients with increased metabolic demand e.g. sepsis, patients with an oxygen requirement prior to RSI, or patients with underlying conditions that predisposes to hypoxia e.g. obesity.
For many years anaesthetists have used end-tidal oxygen (ETO2) levels to guide the effectiveness of preoxygenation. ETO2 measures the exhaled oxygen concentration and is a marker of the oxygen concentration in the alveoli. Prior to induction, anaesthetists most commonly preoxygenate with a face-mask seal via either a circle circuit, Mapleson circuit, or bag valve mask. ETO2 provides an objective measurement of preoxygenation efficacy. The Difficult Airway Society guidelines suggest aiming for an ETO2 of ≥87% prior to commencing RSI.(7) ETO2 levels are not routinely measured in Emergency Departments.
Currently, it is not possible to measure the effectiveness of preoxygenation in the ED. Pulse-wave oximetry reflects peripheral oxygen saturation and not the pulmonary oxygen concentration. Therefore, to attempt to optimize preoxygenation the emergency clinician currently can only use time as a surrogate. The typically recommended duration of preoxygenation is > 3 minutes.
Recently, the investigators conducted two multi-site studies (Ethics identifier: 2019/ETH06644) that investigated the use of ETO2 in the ED.(8, 9) The first study was conducted with clinicians blinded to the ETO2 result (8). The investigators demonstrated that preoxygenation was uniformly poor with only 26% of patients achieving the required target ETO2 of ≥85%. The investigators then completed a second study where clinicians had access to ETO2 values and found that the proportion of patients reaching levels ≥85% was improved to 67% of patients. (9) The prevalence of hypoxemia (SpO2 \<90%) in the group blinded to ETO2 was 18% (n=18, 95% CI: 11% to 27%) and was 8% in the group where ETO2 was available (n = 8, 95% CI: 4% to 15%). These studies indicate that the use of ETO2 may substantially improve preoxygenation in the ED and therefore reduce the risk of hypoxia.
These studies, however, were focused on preoxygenation practices and not patient-oriented outcomes (hypoxia) and were limited in design and resources. Consequently, it is still unclear whether the use of ETO2 in the ED leads to improved clinical outcomes.
RATIONALE FOR PERFORMING THE STUDY
The aim of this study is to determine the effectiveness of ETO2 monitoring in preventing desaturation for patients with a high risk of hypoxia undergoing RSI in ED.
HYPOTHESIS
The investigators hypothesise that the use of ETO2 monitoring leads to reduced rates of oxygen desaturation during the peri-intubation period compared to when it is not used.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
This study's planned enrollment of 1,400 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Browse Hypoxia studies →Sydney Local Health District is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Compared within Hypoxia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient is deemed to be at a high risk of hypoxia during RSI as per the treating ED clinician, as defined by:
Any patient with respiratory pathology based on clinical or radiological findings. Including, but not limited to:
Any patient with high oxygen consumption. Including, but not limited to:
Any underlying patient condition that may predispose to hypoxemia. Including, but not limited to:
Exclusion Criteria:
The control period includes a period whereby clinicians will not have access to ETO2 monitoring and routine RSI practices will be documented including all study variables. At all institutions, RSI is performed in a similar manner, utilising an airway checklist. There is no 'standard operating procedure' for RSI in any of the EDs and methods, therefore, vary depending on clinician preference and the condition of the patient, however, each site is a tertiary-level, university teaching hospital and therefore clinical practice is up to date and evidence-based. Standard preoxygenation methods in the Emergency department often consist of a bag-valve mask, with or without a PEEP valve, set at 15L/min, or the use of non-invasive ventilation or a non-rebreather mask, with or without a nasal cannula, set at 15 L/min or flush rate oxygen (\>40 L/min). US sites have access to high-flow (\>30L/min) oxygen. This is the only difference in the preoxygenation method.
For all patients involved in the study, the only intervention will be the use of ETO2 to guide preoxygenation. All aspects of RSI will be at the discretion of the treating clinician including sedative/paralytic medications, positioning of the patient, preoxygenation method, intubation techniques and post-intubation sedation. Clinicians will be encouraged to aim for the highest ETO2 result possible with a goal of \>85%. Clinicians will be able to view the ETO2 values and can decide on any changes to the preoxygenation techniques if deemed necessary. These techniques may include improved patient positioning, improved face mask seal, increased oxygen flow, length of preoxygenation time, or altering the preoxygenation device.
Device: End-tidal oxygen monitor
The only additional equipment required for this study is the Philips™ IntelliVue G7m Gas Analyser Module 866173. This provides a non-dispersive infrared measurement of respiratory gases and a paramagnetic measurement of oxygen. At Lincoln Medical Center, the gas analyser used will be a Philips G5 gas analyser connected to a Philips Intellivue MP 70. At the University of New Mexico Medical Center, the Masimo root monitor is used. The gas analysers produce display waves for O2 and CO2, together with numerics for end-tidal values for O2 and CO2 and to our knowledge, there are no differences in values between the various devices used. The gas sampling occurs through a side-stream sampling tube at a rate of 200ml/min ±20 ml/min, which is either obtained from a nasal cannula in the spontaneously breathing patient or a sidestream line if connected to a BVM.
Incidence of hypoxia
The proportion of patients that experience oxygenation desaturation (SpO2 \<93%, or \>10% from baseline if SpO2 \<93% at the end of preoxygenation) during the peri-intubation period
Time frame: The time when laryngoscope first enters the mouth to 2 minutes after the endotracheal tube [ETT] is confirmed on waveform capnography
Lowest oxygen saturations
The lowest oxygen saturation (SpO2) during the peri-intubation period
Time frame: The time when laryngoscope first enters the mouth to 2 minutes after the endotracheal tube [ETT] is confirmed on waveform capnography
Time from preoxygenation to endotracheal intubation
Time from preoxygenation to endotracheal intubation
Time frame: Preoxygenation start time to endotracheal intubation confirmation
Incidence of severe oxygen desaturation (SpO2 <80%)
Incidence of severe oxygen desaturation (SpO2 \<80%)
Time frame: Induction of sedative medications and 2 minutes post ETT confirmation
Incidence of very severe oxygen desaturation (SpO2 <70%)
Incidence of very severe oxygen desaturation (SpO2 \<70%)
Time frame: Induction of sedative medications and 2 minutes post ETT confirmation
Incidence of the number of patients with pre-oxygenation method changes to achieve higher ETO2 in intervention arm
Incidence in pre-oxygenation changes in method to deliver higher ETO2: * BVM * BVM+PEEP * HFNP * NIV
Time frame: During preoxygenation
Incidence of the number of patients with pre-oxygenation technique changes to achieve higher ETO2 in intervention arm
Incidence in pre-oxygenation changes in technique to deliver higher ETO2: * Improved mask seal * Increased O2 flow rate * Increased Preoxygenation time
Time frame: During preoxygenation
Number of re-oxygenation events
A re-oxygenation attempt is a failed first attempt at ETT placement followed by administration of an oxygen delivery device (BVM, NIV, supraglottic device) to maintain SpO2 levels
Time frame: During preoxygenation
Cardiovascular complications during RSI
* Bradycardia (HR\< 40 bpm) * Tachycardia (HR\> 120 bpm) * Hypotension (SBP\< 90 mm Hg or a 30mmHg reduction from baseline)
Time frame: Induction of sedative medications and 2 minutes post ETT confirmation
Other complications during RSI
Operator reported aspiration between induction and intubation Oesophageal intubation recognised after the laryngoscope blade has been removed, detected by waveform ETCO2 Cardiac arrest occurred during RSI
Time frame: Induction of sedative medications and 2 minutes post ETT confirmation
Plan to share: Yes — Following publication, individual patient data will be made available for sharing to researchers with 1) a signed data access agreement, 2) research testing a hypothesis, 3) a protocol that has been approved by an institutional review board, and 4) a proposal that has received approval from the principal investigator.
Supporting information: Study protocol, Statistical analysis plan
Time frame: No end date
Access criteria: a signed data access agreement research testing a hypothesis a protocol that has been approved by an institutional review board a proposal that has received approval from the principal investigator
Started Aug 2024 (actual). Primary completion is estimated for Dec 2025, 16 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 16 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sydney Local Health District